Mark Ammirati

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Specificity determinants of human cathepsin s revealed by crystal structures of complexes.

Traian Sulea, Miroslaw Cygler, Robert Ménard, 2003, Biochemistry.